Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Lack of antiviral activity of darunavir against SARS-CoV-2

OBJECTIVES: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives

METHODS: Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for the treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed

RESULTS: DRV showed no antiviral activity against SARS-CoV-2 at clinically relevant concentrations (EC50 > 100 μM). Remdesivir, used as a positive control, demonstrated potent antiviral activity (EC50 = 0.38 μM)

CONCLUSIONS: Overall, the data do not support the use of DRV for the treatment of COVID-19

Year of Publication: 2020
Contained in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases Vol. 97 (2020), p. 7-10
All journal articles: Search for all articles in this journal
Language: English
Contributors: De Meyer, Sandra | Author
Bojkova, Denisa
Cinatl, Jindrich
Van Damme, Ellen
Buyck, Christophe
Van Loock, Marnix
Woodfall, Brian
Ciesek, Sandra
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: COVID-19
In vitro
Journal Article
SARS-CoV-2
YO603Y8113
Additional Keywords: *Coronavirus Infections
*Pandemics
*Pneumonia, Viral
Antiviral Agents
Betacoronavirus
Cell Line
Cell Survival
Darunavir
Humans
ISSN: 1878-3511
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 03.08.2020
Date Revised 09.09.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32479865
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1016/j.ijid.2020.05.085
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03703nma a2200793 c 4500
001 NLM311494196
003 DE-601
005 20200909214340.0
007 cr uuu---uuuuu
008 200602s2020 000 0 eng d
024 7 |a 10.1016/j.ijid.2020.05.085  |2 doi 
028 5 2 |a pubmed20n1332.xml 
035 |a S1201-9712(20)30392-1 
035 |a (DE-599)NLM32479865 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a De Meyer, Sandra 
245 1 0 |a Lack of antiviral activity of darunavir against SARS-CoV-2  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 03.08.2020 
500 |a Date Revised 09.09.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright © 2020. Published by Elsevier Ltd. 
520 |a OBJECTIVES: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives 
520 |a METHODS: Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for the treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed 
520 |a RESULTS: DRV showed no antiviral activity against SARS-CoV-2 at clinically relevant concentrations (EC50 > 100 μM). Remdesivir, used as a positive control, demonstrated potent antiviral activity (EC50 = 0.38 μM) 
520 |a CONCLUSIONS: Overall, the data do not support the use of DRV for the treatment of COVID-19 
611 2 7 |a Journal Article  |2 gnd 
653 2 |a Antiviral Agents  |6 D000998  |a therapeutic use  |6 Q000627 
653 2 |a Betacoronavirus  |6 D000073640  |a *drug effects  |6 Q000187 
653 2 |a Cell Line  |6 D002460 
653 2 |a Cell Survival  |6 D002470  |a drug effects  |6 Q000187 
653 2 |a *Coronavirus Infections  |6 D018352  |a drug therapy  |6 Q000188 
653 2 |a Darunavir  |6 D000069454  |a *therapeutic use  |6 Q000627 
653 2 |a Humans  |6 D006801 
653 2 |a *Pandemics  |6 D058873 
653 2 |a *Pneumonia, Viral  |6 D011024  |a drug therapy  |6 Q000188 
655 7 |a COVID-19  |2 gnd 
655 7 |a Darunavir  |2 gnd 
655 7 |a In vitro  |2 gnd 
655 7 |a SARS-CoV-2  |2 gnd 
655 7 |a Antiviral Agents  |2 gnd 
655 7 |a Darunavir  |2 gnd 
655 7 |a YO603Y8113  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a Darunavir 
689 1 2 |a In vitro 
689 1 3 |a SARS-CoV-2 
689 1 |5 DE-601 
689 2 0 |a Antiviral Agents 
689 2 1 |a Darunavir 
689 2 2 |A r  |a YO603Y8113 
689 2 |5 DE-601 
700 1 |a Bojkova, Denisa 
700 1 |a Cinatl, Jindrich 
700 1 |a Van Damme, Ellen 
700 1 |a Buyck, Christophe 
700 1 |a Van Loock, Marnix 
700 1 |a Woodfall, Brian 
700 1 |a Ciesek, Sandra 
773 0 8 |i in  |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases  |g Vol. 97 (2020), p. 7-10  |q 97<7-10  |w (DE-601)NLM094733481  |x 1878-3511 
856 4 1 |u http://dx.doi.org/10.1016/j.ijid.2020.05.085  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 97  |j 2020  |b 30  |c 08  |h 7-10